Correlation Between Terns Pharmaceuticals and DiaMedica Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Terns Pharmaceuticals and DiaMedica Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Terns Pharmaceuticals and DiaMedica Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Terns Pharmaceuticals and DiaMedica Therapeutics, you can compare the effects of market volatilities on Terns Pharmaceuticals and DiaMedica Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Terns Pharmaceuticals with a short position of DiaMedica Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Terns Pharmaceuticals and DiaMedica Therapeutics.

Diversification Opportunities for Terns Pharmaceuticals and DiaMedica Therapeutics

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Terns and DiaMedica is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Terns Pharmaceuticals and DiaMedica Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on DiaMedica Therapeutics and Terns Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Terns Pharmaceuticals are associated (or correlated) with DiaMedica Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of DiaMedica Therapeutics has no effect on the direction of Terns Pharmaceuticals i.e., Terns Pharmaceuticals and DiaMedica Therapeutics go up and down completely randomly.

Pair Corralation between Terns Pharmaceuticals and DiaMedica Therapeutics

Given the investment horizon of 90 days Terns Pharmaceuticals is expected to under-perform the DiaMedica Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Terns Pharmaceuticals is 1.01 times less risky than DiaMedica Therapeutics. The stock trades about -0.23 of its potential returns per unit of risk. The DiaMedica Therapeutics is currently generating about -0.09 of returns per unit of risk over similar time horizon. If you would invest  534.00  in DiaMedica Therapeutics on December 29, 2024 and sell it today you would lose (120.00) from holding DiaMedica Therapeutics or give up 22.47% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Terns Pharmaceuticals  vs.  DiaMedica Therapeutics

 Performance 
       Timeline  
Terns Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Terns Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
DiaMedica Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days DiaMedica Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Terns Pharmaceuticals and DiaMedica Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Terns Pharmaceuticals and DiaMedica Therapeutics

The main advantage of trading using opposite Terns Pharmaceuticals and DiaMedica Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Terns Pharmaceuticals position performs unexpectedly, DiaMedica Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DiaMedica Therapeutics will offset losses from the drop in DiaMedica Therapeutics' long position.
The idea behind Terns Pharmaceuticals and DiaMedica Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Complementary Tools

AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets